

212	Unknown †	Intervention:	Biological: Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells
		Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib	
		Condition:	Renal Cell Cancer
213	Recruiting	Intervention:	Biological: Autologous renal cell vaccine based on DNP modified cells
		Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission	
		Conditions:	Acute Myelogenous Leukemia; AML
214	Recruiting	Interventions:	Biological: DC AML Vaccine; Drug: CT-011
		Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxin in Patients With High-Risk Neuroblastoma	
		Condition:	Neuroblastoma
215	Unknown †	Interventions:	Biological: Neuroblastoma Vaccine; Drug: Cytoxin
		How Our Immune System Can Help Fight Cancer	
		Condition:	Ovarian Cancer
216	Completed	Intervention:	
		Immune Responses To Antigen-Bearing Dendritic Cells in Patients With Malignancy	
		Condition:	Melanoma
217	Completed	Intervention:	Biological: dendritic cell vaccine
		Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients	
		Condition:	Melanoma
218	Active, not recruiting	Interventions:	Drug: Daclizumab; Biological: Dendritic cells
		Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Breast Cancer	
		Condition:	Breast Cancer
219	Active, not recruiting	Intervention:	Biological: E75 + GM-CSF vaccine
		Safety and Efficacy Study of HER2/Neu (E75) Vaccine in Node-Positive Breast Cancer Patients	
		Condition:	Breast Cancer
220	Recruiting	Intervention:	Biological: E75 + GM-CSF vaccine
		Vaccine Therapy in Treating Patients With Breast Cancer	
		Condition:	Breast Cancer
221	Completed	Interventions:	Biological: GP2 peptide + GM-CSF vaccine; Biological: GM-CSF (sargramostim); Biological: AE37 + GM-CSF vaccine
		Treatment of B-CLL With Human IL-2 and CD40 Ligand and Plasmid Gene Modified Autologous Tumor Cells	
		Conditions:	Leukemia; Leukemia, B-Cell, Chronic
222	Completed	Intervention:	Biological: IL-2 AND HUMAN CD40 LIGAND PLASMID GENE MODIFIED AUTOLOGOUS TUMOR CELLS
		Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma	
		Condition:	Neuroblastoma
223	Completed	Intervention:	Drug: Interleukin-2
		Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor Cells	
		Condition:	Chronic Lymphocytic B-Leukemia
224	Withdrawn	Intervention:	Biological: Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells
		S0348 Vaccine Therapy in Treating Patients With Stage III B or Stage IV Breast Cancer in Remission	
		Condition:	Breast Cancer

		Interventions:	Drug: recombinant modified vaccinia Ankara-5T4 vaccine; Procedure: adjuvant therapy; Procedure: recombinant viral vaccine therapy
225	Completed	Prospective Trial of Vaccine Responses Against Pneumococcus and Influenza in Adult Cancer Patients 65 Years of Age and Older	
		Conditions:	Breast Cancer; Lung Cancer; Prostate Cancer
		Interventions:	Biological: inactivated influenza vaccine and the 23- valent pneumococcal vaccine; Biological: inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)
226	Active, not recruiting	Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant	
		Condition:	Prostate Cancer
		Intervention:	Biological: pTVG-HP with rhGM-CSF
227	Active, not recruiting	Phase I Trial of TGFB2-Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine for Advanced Cancer	
		Condition:	Carcinoma, Advanced Metastatic
		Intervention:	Biological: TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine
228	Recruiting	Tumor Cell Vaccines With ISCOMATRIX(Trademark) Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal	
		Conditions:	Mesothelioma; Esophageal Cancer; Lung Cancer
		Interventions:	Drug: Celecoxib; Drug: ISCOMATRIX (TM) Adjuvant; Biological: Autologous Tumor Cell Vaccine
229	Recruiting	Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer	
		Conditions:	Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity Cancer; Stage IIA Fallopian Tube Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Primary Peritoneal Cavity Cancer; Stage IIB Fallopian Tube Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Primary Peritoneal Cavity Cancer; Stage IIC Fallopian Tube Cancer; Stage IIC Ovarian Epithelial Cancer; Stage IIC Primary Peritoneal Cavity Cancer; Stage IIIA Fallopian Tube Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Fallopian Tube Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Fallopian Tube Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Primary Peritoneal Cavity Cancer; Stage IV Fallopian Tube Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Primary Peritoneal Cavity Cancer
		Interventions:	Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine; Drug: sirolimus; Other: laboratory biomarker analysis;
230	Recruiting	Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients	
		Condition:	HPV-related Head and Neck Cancer
		Intervention:	Biological: pNGVL-4a-CRT/E7 (detox) DNA vaccine
231	Withdrawn	GI-4000 With Adoptive Transfer in Pancreatic Cancer	
		Condition:	Pancreatic Cancer
		Interventions:	Other: Screening; Biological: GI-4000 Vaccine; Biological: GI-4000 Vaccine + Activated T Cells; Biological: Surgical Evaluation after Vaccine #4
232	Recruiting	Cyclophosphamide and Vaccine Therapy in Treating Patients With Stage II-III Breast, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	

		Conditions:	Recurrent Breast Cancer; Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Ovarian Germ Cell Tumor; Recurrent Primary Peritoneal Cavity Cancer; Stage IIA Ovarian Epithelial Cancer; Stage IIA Ovarian Germ Cell Tumor; Stage IIA Primary Peritoneal Cavity Cancer; Stage IIB Ovarian Epithelial Cancer; Stage IIB Ovarian Germ Cell Tumor; Stage IIB Primary Peritoneal Cavity Cancer; Stage IIC Ovarian Epithelial Cancer; Stage IIC Ovarian Germ Cell Tumor; Stage IIC Primary Peritoneal Cavity Cancer; Stage IIIA Breast Cancer; Stage IIIA Ovarian Epithelial Cancer; Stage IIIA Ovarian Germ Cell Tumor; Stage IIIA Primary Peritoneal Cavity Cancer; Stage IIIB Breast Cancer; Stage IIIB Ovarian Epithelial Cancer; Stage IIIB Ovarian Germ Cell Tumor; Stage IIIB Primary Peritoneal Cavity Cancer; Stage IIIC Breast Cancer; Stage IIIC Ovarian Epithelial Cancer; Stage IIIC Ovarian Germ Cell Tumor; Stage IIIC Primary Peritoneal Cavity Cancer
		Interventions:	Drug: Cyclophosphamide; Biological: multi-epitope folate receptor alpha peptide vaccine; Other: laboratory
233	Recruiting	Phase Ib Trial of Folate Binding Protein Vaccine in Ovarian Cancer	
		Conditions:	Ovarian Cancer; Endometrial Cancer
		Interventions:	Biological: E39 peptide vaccine; Other: Clinical tracking for disease progression/recurrence
234	Active, not recruiting	Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer	
		Conditions:	Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
		Interventions:	Biological: rilimogene-galvacirepvec; Biological: fowlpox-PSA-TRICOM vaccine; Drug: docetaxel; Drug:
235	Completed	DC Vaccine Combined With IL-2 and IFN α-2a in Treating Patients With mRCC	
		Condition:	Kidney Cancer
		Interventions:	Biological: Aldesleukin.; Biological: autologous tumor cell vaccine; Biological: recombinant interferon alfa
236	Recruiting	Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors	
		Conditions:	Adult Anaplastic Astrocytoma; Adult Anaplastic Oligodendroglioma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Mixed Glioma; Adult Primary Hepatocellular Carcinoma; Chondrosarcoma; Clear Cell Sarcoma of the Kidney; Conjunctival Kaposi Sarcoma; Estrogen Receptor-negative Breast Cancer; Estrogen Receptor-positive Breast Cancer; Hormone-resistant Prostate Cancer; Limited Stage Small Cell Lung Cancer; Localized Resectable Adult Primary Liver Cancer; Male Breast Cancer; Mast Cell Sarcoma; Ovarian Sarcoma; Recurrent Adult Brain Tumor; Recurrent Adult Primary Liver Cancer; Recurrent Adult Soft Tissue Sarcoma; Recurrent Bladder Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Esophageal Cancer; Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor; Recurrent Gastric Cancer; Recurrent Kaposi Sarcoma; Recurrent Melanoma; Recurrent Non-small Cell Lung Cancer; Recurrent Pancreatic Cancer; Recurrent Sarcoma; Recurrent Squamous Cell Carcinoma of the Head and Neck; Recurrent Squamous Cell Carcinoma of the Lung; Recurrent Squamous Cell Carcinoma of the Stomach; Recurrent Squamous Cell Carcinoma of the Uterus; Recurrent Testicular Cancer; Recurrent Uterine Cancer; Recurrent Uterine Sarcoma
		Interventions:	Drug: sirolimus; Other: laboratory biomarker analysis; Biological: DEC-205-NY-ESO-1 fusion protein vaccine
237	Recruiting	Immunization With a Pentavalent Vaccine Composed of KLH-conjugates of GD2L, GD3L, Globo H, Fucosyl GM1, and N-Propionylated	
		Condition:	Lung Cancer
		Interventions:	Biological: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant; Biological: Biological/Vaccine: vaccine comprised of KLH conjugates of
238	Recruiting	Safety of Labeled Dendritic Cell (DC) Vaccines and Feasibility of Tracking by Magnetic Resonance Imaging (MRI)	
		Conditions:	Colorectal Neoplasms; Colorectal Cancer; Colorectal Carcinoma; Colorectal Tumors; Neoplasms, Colorectal
		Intervention:	Biological: DC Vaccine
239	Completed	Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines	
		Condition:	Prostate Cancer

240	Recruiting	Intervention:	Biological: Immunotherapy allogeneic GM-CSF secreting cellular vaccine
		Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors	
		Conditions:	Cancer Survivor; Human Papilloma Virus Infection
241	Completed Has	Interventions:	Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: laboratory biomarker analysis; Other: survey administration; Other: medical chart review
		Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants	
		Conditions:	Cervical Cancer; Precancerous Condition
242	Recruiting	Interventions:	Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine; Biological: hepatitis A inactivated virus
		Vaccine Therapy in Treating Patients With Metastatic Breast Cancer	
		Conditions:	Recurrent Breast Cancer; Stage IV Breast Cancer; Unspecified Adult Solid Tumor, Protocol Specific
243	Recruiting	Interventions:	Biological: adenovirus-p53 transduced dendritic cell vaccine; Drug: 1-methyl-d-tryptophan; Other: laboratory
		Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy	
		Conditions:	Breast Cancer; Colon Cancer; Bladder Cancer
244	Active, not recruiting	Interventions:	Drug: Glycosylated Recombinant Human Interleukin-7; Biological: Diphtheria-Tetanus Vaccine; Biological: Polio
		Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab	
		Conditions:	Fallopian Tubes Cancer; Ovarian Cancer; Peritoneal Cancer
245	Recruiting	Intervention:	Biological: bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
		Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients	
		Condition:	Recurrent Epithelial Ovarian Cancer
246	Completed	Intervention:	Biological: DC-006 vaccine
		Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer	
		Conditions:	Adenocarcinoma of the Colon; Adenocarcinoma of the Gallbladder; Adenocarcinoma of the Pancreas; Adenocarcinoma of the Rectum; Adult Primary Hepatocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Gallbladder; Diffuse Adenocarcinoma of the Stomach; Intestinal Adenocarcinoma of the Stomach; Male Breast Cancer; Mixed Adenocarcinoma of the Stomach; Ovarian Endometrioid Adenocarcinoma; Paget Disease of the Breast With Intraductal Carcinoma; Paget Disease of the Breast With Invasive Ductal Carcinoma; Recurrent Adult Primary Liver Cancer; Recurrent Breast Cancer; Recurrent Colon Cancer; Recurrent Gallbladder Cancer; Recurrent Gastric Cancer; Recurrent Malignant Testicular Germ Cell Tumor; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Recurrent Salivary Gland Cancer; Salivary Gland Adenocarcinoma; Stage II Malignant Testicular Germ Cell Tumor; Stage II Pancreatic Cancer; Stage III
247	Recruiting	Interventions:	Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine; Biological: sargramostim; Biological: recombinant
		Vaccine Therapy in Treating Patients With Stage III-IV or Recurrent Ovarian Cancer	
		Conditions:	Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor
248	Recruiting	Interventions:	Biological: pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine; Other: laboratory biomarker analysis
		Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Patients With Stage II-IV HER2-Positive Breast Cancer	
		Conditions:	HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer
249	Terminated	Interventions:	Biological: HER-2/neu peptide vaccine; Biological: sargramostim; Drug: rintatolimod; Other: laboratory
		Vaccine Therapy in Treating Patients With Metastatic Breast Cancer	
		Conditions:	Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
		Interventions:	Biological: recombinant vaccinia-MUC1 vaccine; Biological: recombinant vaccinia-TRICOM vaccine; Other:

250	Completed	Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma
		Condition: Melanoma (Skin) Interventions: Biological: autologous tumor cell vaccine; Biological: therapeutic autologous dendritic cells
251	Suspended	Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer
		Condition: Prostate Cancer Interventions: Biological: allogeneic tumor cell vaccine; Biological: therapeutic autologous dendritic cells
252	Unknown †	Vaccine Therapy and Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Liver Metastases Due to Colorectal Cancer
		Conditions: Colorectal Cancer; Metastatic Cancer Interventions: Biological: GM-K562 cell vaccine; Biological: allogeneic tumor cell vaccine; Drug: cyclophosphamide; Genetic:
253	Recruiting	Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer
		Conditions: Recurrent Colon Cancer; Recurrent Gastric Cancer; Recurrent Pancreatic Cancer; Recurrent Rectal Cancer; Stage III Colon Cancer; Stage III Gastric Cancer; Stage III Pancreatic Cancer; Stage III Rectal Cancer; Stage IV Colon Cancer; Stage IV Gastric Cancer; Stage IV Pancreatic Cancer; Stage IV Rectal Cancer Interventions: Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Other: flow cytometry; Other:
254	Completed	Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer
		Condition: Prostate Cancer Interventions: Biological: recombinant fowlpox-prostate specific antigen vaccine; Biological: recombinant vaccinia prostate-
255	Active, not recruiting	Alpha-type-1 Dendritic Cell-based Vaccines in Patients With Metastatic Colorectal Cancer
		Condition: Metastatic Colorectal Cancer Intervention: Biological: DC-based vaccine
256	Unknown †	Vaccine Therapy in Treating Patients With Kidney Cancer
		Condition: Kidney Cancer Interventions: Biological: autologous tumor cell vaccine; Biological: therapeutic autologous dendritic cells
257	Recruiting	Trial of Bi-shRNA-furin and Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) Augmented Autologous Tumor Cell Vaccine for
		Condition: Solid Tumors Intervention: Biological: FANG
258	Terminated	S0122: Combination Chemotherapy, Radiation Therapy, and Vaccine Therapy in Limited-Stage Small Cell Lung Cancer
		Condition: Lung Cancer Interventions: Biological: monoclonal antibody 11D10 anti-idiotype vaccine; Biological: monoclonal antibody GD2 anti-idiotype
259	Active, not recruiting	Vaccine Therapy in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery
		Condition: Pancreatic Cancer Intervention: Biological: allogenic GM-CSF plasmid-transfected pancreatic tumor cell vaccine
260	Completed	153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
		Condition: Prostate Cancer Interventions: Radiation: Samarium Sm 153 lexidronam pentasodium; Biological: Sargramostim; Biological: Recombinant
261	Recruiting	Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer
		Condition: Breast Neoplasms Intervention: Biological: 9 Peptides from Her-2/neu, CEA, & CTA

262	Recruiting	Safety Study of BPX-201 Dendritic Cell Vaccine Plus AP1903 in Metastatic Castrate Resistant Prostate Cancer	
		Condition:	Castrate Resistant Prostate Cancer
		Intervention:	Biological: BPX-201 vaccine plus AP1903
263	Completed	p53 Synthetic Long Peptides Vaccine With Cyclophosphamide for Ovarian Cancer	
		Condition:	Ovarian Cancer
		Interventions:	Drug: P53-SLP vaccine; Drug: Cyclophosphamide
264	Recruiting	MUC1 Vaccine for Triple-negative Breast Cancer	
		Conditions:	Breast Cancer; Inflammatory Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Triple-negative Breast Cancer
		Interventions:	Biological: MUC-1 peptide vaccine; Biological: poly ICLC; Biological: MUC1 peptide-poly-ICLC adjuvant vaccine;
265	Unknown †	Measles Vaccine in Patients With Measles Virus-Positive, Advanced Non-Small Cell Lung Cancer	
		Conditions:	Non-Small Cell Lung Cancer; Measles
		Intervention:	Biological: attenuated measles vaccine
266	Active, not recruiting	Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor	
		Conditions:	Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancer
		Interventions:	Drug: GM-CSF; Biological: Dendritic Cell/Tumor Fusion Vaccine; Drug: imiquimod
267	Completed	Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer,	
		Conditions:	Leukemia; Lung Cancer; Malignant Mesothelioma; Myelodysplastic Syndromes; Primary Peritoneal Cavity
		Interventions:	Biological: WT-1 analog peptide vaccine; Biological: incomplete Freund's adjuvant; Biological: sargramostim;
268	Recruiting	Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12	
		Condition:	Breast Cancer
		Interventions:	Biological: Dendritic Cell/Tumor Fusion Vaccine; Drug: Interleukin-12
269	Completed	Vaccine Therapy Plus QS21 in Treating Patients With Prostate Cancer	
		Condition:	Prostate Cancer
		Interventions:	Biological: MUC-2-Globo H-KLH conjugate vaccine; Biological: QS21
270	Recruiting	Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer	
		Condition:	Prostate Cancer
		Interventions:	Biological: sipuleucel-T; Biological: DNA Vaccine
271	Recruiting	Vaccine Therapy in Treating Patients With Metastatic Solid Tumors	
		Conditions:	Malignant Solid Tumour; Breast Cancer; Malignant Tumor of Colon; GIST; Ovarian Cancer
		Intervention:	Biological: HER-2 vaccine
272	Completed	Vaccine Therapy Plus Biological Therapy in Treating Patients With Prostate Cancer	
		Condition:	Prostate Cancer
		Interventions:	Biological: GPI-0100; Biological: MUC-2-Globo H-KLH conjugate vaccine
273	Active, not recruiting	Trivalent Influenza Vaccine in Preventing Flu in Patients With Central Nervous System Tumors	
		Condition:	Central Nervous System Neoplasm
		Interventions:	Biological: trivalent influenza vaccine; Other: laboratory biomarker analysis
274	Active, not recruiting	Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer	
		Conditions:	HER2-positive Breast Cancer; Stage III Ovarian Epithelial Cancer; Stage III Ovarian Germ Cell Tumor; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer; Stage IV Breast Cancer; Stage IV Ovarian Epithelial Cancer; Stage IV Ovarian Germ Cell Tumor

275	Terminated	Interventions:	Biological: pNGVL3-hICD vaccine; Biological: sargramostim; Other: flow cytometry; Other: immunologic
		Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer)	
		Conditions:	Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer
276	Active, not recruiting	Interventions:	Biological: recombinant fowlpox-prostate specific antigen vaccine; Biological: recombinant vaccinia prostate-
		Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer	
		Condition:	Non Small Cell Lung Cancer
277	Active, not recruiting	Intervention:	Biological: DRibble vaccine
		Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer	
		Condition:	Lung Cancer
278	Active, not recruiting	Interventions:	Biological: Autologous dendritic cell-adenovirus p53 vaccine; Drug: Carboplatin; Drug: Etoposide
		Prospective Trial of Vaccine Responses in Childhood Cancer Survivors	
		Conditions:	Childhood Cancer; Multiple Diseases
279	Active, not recruiting	Interventions:	Biological: Immunization Schedule patients <7 years.; Biological: Immunization Schedule patients > or = to 7 years and <11 years of age; Biological: Immunization Schedule patients > or = to 11 years of age
		Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme	
		Condition:	Brain and Central Nervous System Tumors
280	Active, not recruiting	Interventions:	Biological: glioblastoma multiforme multipeptide vaccine IMA950; Biological: sargramostim; Drug: temozolomide; Other: laboratory biomarker analysis; Other: pharmacological study; Procedure: adjuvant therapy; Radiation:
		Decitabine, Vaccine Therapy, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Epithelial	
		Conditions:	Recurrent Fallopian Tube Cancer; Recurrent Ovarian Epithelial Cancer; Recurrent Primary Peritoneal Cavity
281	Withdrawn	Interventions:	Drug: decitabine; Biological: NY-ESO-1 peptide vaccine; Drug: pegylated liposomal doxorubicin hydrochloride;
		Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer	
		Condition:	Breast Cancer
282	Active, not recruiting	Intervention:	Biological: Ad-sig-hMUC-1/ecdCD40L vaccine
		Alpha-Type 1 Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in	
		Condition:	Prostate Cancer
283	Completed	Interventions:	Biological: androgen ablation + dendritic cell vaccine; Biological: androgen ablation plus dendritic cell vaccine
		A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer	
		Condition:	Epithelial Ovarian, Tubal or Peritoneal Cancer
284	Recruiting	Intervention:	Biological: tumor peptide vaccine
		Vaccine Therapy in Treating Patients With Stage IV Breast Cancer	
		Conditions:	HER2-positive Breast Cancer; Male Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
285	Completed	Interventions:	Biological: HER-2/neu peptide vaccine; Procedure: leukapheresis; Biological: ex vivo-expanded HER2-specific T
		Phase II Study of a B7-1 Gene-Modified Autologous Tumor Cell Vaccine and Systemic IL-2	
		Condition:	Kidney Cancer
286	Active, not recruiting	Interventions:	Biological: Interleukin-2; Biological: B7-1
		Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer	
		Condition:	Non-small Cell Lung Cancer
286	Active, not recruiting	Interventions:	Biological: HS110 vaccine; Biological: Placebo

287	Suspended	DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer	
		Condition:	Non-Small Cell Lung Cancer - Completely Resectable
		Intervention:	Biological: L-Vax: Autologous, DNP-Modified NSCLC Vaccine
288	Active, not recruiting	Vaccine Therapy With Either Neoadjuvant or Adjuvant Chemotherapy and Adjuvant Radiation Therapy in Treating Women With p53-	
		Condition:	Breast Cancer
		Intervention:	Biological: autologous dendritic cell-adenovirus p53 vaccine
289	Completed	A Study of a Live Intranasal Influenza Vaccine in Children With Cancer	
		Condition:	Cancer
		Interventions:	Biological: FluMist; Biological: Inactivated influenza vaccine
290	Completed Has	Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals	
		Conditions:	Human Papillomavirus (HPV) Infection; Cervical Neoplasia
		Interventions:	Biological: Cervarix™; Biological: Havrix™-based investigational formulation
291	Unknown †	Dose Finding Study of a DNA Vaccine Delivered With Intradermal Electroporation in Patients With Prostate Cancer	
		Condition:	Prostate Cancer
		Interventions:	Biological: pVAXrcPSAv53I (DNA encoding rhesus PSA); Device: DERMA VAX™ intradermal DNA delivery system
292	Completed	Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be	
		Condition:	Lung Cancer
		Interventions:	Biological: recombinant fowlpox GM-CSF vaccine adjuvant; Biological: recombinant fowlpox-CEA(6D)/TRICOM
293	Enrolling by invitation	Evaluation of Long-term HPV Vaccine Efficacy	
		Condition:	Uterine Cervical Cancer
		Intervention:	Procedure: Screening for cervical cancer
294	Completed	An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant	
		Conditions:	Prostate Cancer; Breast Cancer; Lung Cancer; Colorectal Cancer; Head and Neck Cancer
		Interventions:	Biological: GI-6207 [Recombinant Saccharomyces Cerevisia; Drug: (Yeast CEA Vaccine)(GI-6207)[Recombinant
295	Terminated	p53 Vaccine for Ovarian Cancer	
		Condition:	Ovarian Neoplasm
		Interventions:	Biological: aldesleukin; Biological: incomplete Freund's adjuvant; Biological: p53 peptide vaccine; Biological: sargramostim; Biological: therapeutic autologous dendritic cells; Procedure: in vitro-treated peripheral blood stem
296	Unknown †	Monoclonal Antibody Therapy and/or Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer	
		Condition:	Colorectal Cancer
		Interventions:	Biological: BCG vaccine; Biological: monoclonal antibody 105AD7 anti-idiotypic vaccine; Drug: alum adjuvant
297	Completed	Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising	
		Conditions:	Neoplasms, Prostate; Prostate Cancer
		Intervention:	Biological: P501-AS15 vaccine
298	Recruiting	Ovarian Dendritic Cell Vaccine Trial	
		Condition:	Ovarian Cancer

		Interventions:	Biological: Ontak DC; Biological: DC vaccination; Drug: Ontak
299	Completed	<u>Vaccine and Antibody Treatment of Prostate Cancer</u>	
		Condition:	Prostatic Neoplasms
		Interventions:	Biological: PROSTVAC-V/TRICOM; Biological: PROSTVAC-F/TRICOM; Drug: MDX-010; Drug: Sargramostim
300	Withdrawn	<u>Ex Vivo Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV</u>	
		Conditions:	HER2-positive Breast Cancer; Male Breast Cancer; Stage IV Breast Cancer
		Interventions:	Biological: HER-2/neu peptide vaccine; Drug: cyclophosphamide; Biological: ex vivo-expanded HER2-specific T cells; Other: laboratory biomarker analysis; Other: flow cytometry; Other: immunoenzyme technique
301	Recruiting	<u>Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery</u>	
		Conditions:	Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
		Interventions:	Biological: falimarev; Biological: inalimarev; Biological: sargramostim; Other: laboratory biomarker analysis
302	Withdrawn	<u>Cyclin B1 Peptide Pulsed Autologous Dendritic Cell Vaccine for Resectable Non-Small Cell Lung Cancer</u>	
		Condition:	Non-small Cell Lung Cancer
		Intervention:	Biological: Cyclin B1 Peptide
303	Withdrawn	<u>Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary</u>	
		Conditions:	Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
		Interventions:	Biological: immunological adjuvant OPT-821; Biological: polyvalent antigen-KLH conjugate vaccine
304	Terminated	<u>Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy</u>	
	Has	Condition:	Lung Cancer
		Interventions:	Biological: Allogeneic B7.1/HLA-A1 transfected tumor cell vaccine; Other: Placebo
305	Completed	<u>Vaccine Therapy Plus QS21 in Treating Patients With Progressive Prostate Cancer</u>	
		Condition:	Prostate Cancer
		Interventions:	Biological: MUC-2-KLH vaccine; Biological: QS21
306	Withdrawn	<u>CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors</u>	
		Conditions:	Breast Cancer; Colon Cancer; Pancreatic Cancer; Sarcoma; Ovarian Cancer
		Interventions:	Biological: p53: 264-272 peptide; Drug: CT-011
307	Active, not recruiting	<u>Immunogenicity of Fluzone HDA High Dose Influenza Vaccine, In Children With Cancer or HIV</u>	
		Conditions:	HIV; Cancer
		Intervention:	Biological: Fluzone High Dose Vaccine Vs Fluzone
308	Recruiting	<u>Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer</u>	
		Condition:	Non-small Cell Lung Cancer (NSCLC)
		Intervention:	Biological: Vaccine + PolyICLC
309	Recruiting	<u>Vaccine Therapy in Treating Patients With Previously Treated Stage II-III HER2-Positive Breast Cancer</u>	
		Conditions:	HER2-positive Breast Cancer; Male Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer; Stage IIIC Breast Cancer
		Interventions:	Biological: HER-2/neu peptide vaccine; Other: laboratory biomarker analysis
310	Recruiting	<u>OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer</u>	
		Conditions:	Fallopian Tube Cancer; Ovarian Cancer; Primary Peritoneal Cavity Cancer
		Interventions:	Biological: immunological adjuvant OPT-821; Biological: polyvalent antigen-KLH conjugate vaccine

311	Completed	PSA Vaccine Therapy in Treating Patients With Advanced Prostate Cancer	
		Condition:	Prostate Cancer
312	Active, not recruiting	Vaccine Therapy in Treating Patients With Previously Treated Stage II or Stage III Breast Cancer	
		Condition:	Breast Cancer
313	Completed	Vaccine Therapy of Prostate Cancer Patients With Recombinant Soluble Prostate-Specific Membrane Antigen (Rs-PSMA) Plus the	
		Condition:	Prostate Cancer
314	Not yet recruiting	Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)	
		Interventions:	Biological: NY-ESO-1 combined with MPLA; Biological: NY-ESO-1 combined with MPLA vaccine
315	Recruiting	Vaccine Therapy in Preventing Human Papillomavirus Infection in Young HIV-Positive Male Patients Who Have Sex With Males	
		Interventions:	Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine; Other: laboratory
316	Recruiting	Efficacy and Immunogenicity Study of Recombinant Human Papillomavirus Bivalent (Type 16/18)Vaccine	
		Interventions:	Biological: HPV Vaccine; Biological: HEV vaccine
317	Unknown †	HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase I)	
		Interventions:	Biological: VEGFR1, VEGFR2; Drug: Gemcitabine
318	Completed	Multivalent Conjugate Vaccine Trial for Patients With Biochem. Relapsed Prostate Cancer	
		Intervention:	Biological: QS21
319	Active, not recruiting	Vaccine Therapy in Treating Patients Receiving Trastuzumab For HER2-Positive Stage IIIB-IV Breast Cancer	
		Interventions:	Biological: HER-2/neu intracellular domain protein; Procedure: leukapheresis; Other: laboratory biomarker
320	Recruiting	Mammaglobin-A DNA Vaccine for Metastatic Breast Cancer	
		Intervention:	Biological: Mammaglobin-A DNA vaccine
321	Recruiting	Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax	
		Interventions:	Drug: Herceptin; Drug: NeuVax vaccine; Drug: GM-CSF
322	Recruiting	Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer	
		Intervention:	Biological: ADENOVIRUS/PSA VACCINE
323	Withdrawn	A Novel Vaccine for the Treatment of MUC1-expressing Tumor Malignancies	